The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2
Open accessAbstract
Background and purpose: Paclitaxel is highly efficacious in the treatment of breast, head and neck, non‐small cell lung cancers and ovarian carcinoma. For malignant gliomas, paclitaxel is prevented from reaching its target by the presence of the efflux pump P‐glycoprotein (P‐gp) at the blood–brain barrier. We investigated the utilization of a new drug delivery system to increase brain delivery of paclitaxel. Experimental approach: Paclitaxel molecules were conjugated to a brain peptide vector, Angiopep‐2, to provide a paclitaxel–Angiopep‐2 conjugate named ANG1005. We determined the brain uptake capacity, intracellular effects and antitumour properties of ANG1005 in vitro against human tumour cell lines and in vivo in human xenografts. We then determined ANG1005 activity on brain tumours with intracerebral human tumour models in nude mice. Key results: We show by in situ brain perfusion that ANG1005 enters the brain to a greater extent than paclitaxel and bypasses the P‐gp. ANG1005 has an antineoplastic potency similar to that of paclitaxel against human cancer cell lines. We also demonstrate that ANG1005 caused a more potent inhibition of human tumour xenografts than paclitaxel. Finally, ANG1005 administration led to a significant increase in the survival of mice with intracerebral implantation of U87 MG glioblastoma cells or NCI‐H460 lung carcinoma cells. Conclusions and implications: These results demonstrate the antitumour potential of a new drug, ANG1005, and establish that conjugation of anticancer agents with the Angiopep‐2 peptide vector could increase their efficacy in the treatment of brain cancer. British Journal of Pharmacology (2008) 155, 185–197; doi:fn1; published online 23 June 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability
Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of Drug Targeting · doi:10.1080/10611860400015936 · Cited by 742
The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses
Deeken, J. F., & Löscher, W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2854 · Cited by 721
MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS
Louis, D. N. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100043 · Cited by 648
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
ABC Transporters and the Blood-Brain Barrier
Begley, D. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384844 · Cited by 545
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Identification and Design of Peptides as a New Drug Delivery System for the Brain
Demeule, M., Régina, A., Ché, C., Poirier, J., Nguyen, T., Gabathuler, R., Castaigne, J.-P., & Béliveau, R. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131318 · Cited by 462
Self-citationTransport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo
Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhänel, M., Spruß, T., Bernhardt, G., Graeff, C., Färber, L., Gschaidmeier, H., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15451 · Cited by 359
Rousselle, C., Clair, P., Lefauconnier, J.-M., Kaczorek, M., Scherrmann, J.-M., & Temsamani, J. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26466-x · Cited by 357
Crown, J., & O'Leary, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02074-2 · Cited by 352
Lidar, Z., Mardor, Y., Jonas, T., Pfeffer, R., Faibel, M., Nass, D., Hadani, M., & Ram, Z. (2004) · Journal of Neurosurgery · doi:10.3171/jns.2004.100.3.0472 · Cited by 342
Breedveld, P., Beijnen, J. H., & Schellens, J. H. M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.009 · Cited by 323
Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel
Feng, S.-S., Mu, L., Win, K., & Huang, G. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043455909 · Cited by 311
Paclitaxel nanoparticles for the potential treatment of brain tumors
Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.006 · Cited by 299
High transcytosis of melanotransferrin (P97) across the blood–brain barrier
Demeule, M., Poirier, J., Jodoin, J., Bertrand, Y., Desrosiers, R. R., Dagenais, C., Nguyen, T., Lanthier, J., Gabathuler, R., Kennard, M., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01201.x · Cited by 221
Self-citationOlivier, J.-C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., & Couet, W. (1999) · Pharmaceutical Research · doi:10.1023/a:1018947208597 · Cited by 213
Dagenais, C., Rousselle, C., Pollack, G. M., & Scherrmann, J.-M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200002000-00020 · Cited by 202
Multidrug resistance and the role of P-glycoprotein knockout mice
Schinkel, A. H., Mol, C. A. A. M., Wagenaar, E., van Deemter, L., Smit, J. J. M., & Borst, P. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00130-b · Cited by 199
Kemper, E. M., Boogerd, W., Thuis, I., Beijnen, J. H., & van Tellingen, O. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.04.001 · Cited by 177
Nikanjam, M., Gibbs, A. R., Hunt, C. A., Budinger, T. F., & Forte, T. M. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.09.007 · Cited by 165
Targeted delivery across the blood–brain barrier
Gaillard, P. J., Visser, C. C., & de Boer, A. G. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.2.299 · Cited by 131
Cytotoxicity of taxol in vitro against human and rat malignant brain tumors
Cahan, M. A., Walter, K. A., Colvin, O. M., & Brem, H. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686276 · Cited by 116
Cisternino, S., Bourasset, F., Archimbaud, Y., Sémiond, D., Sanderink, G., & Scherrmann, J. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705150 · Cited by 111
Understanding tubulin–Taxol interactions: Mutations that impart Taxol binding to yeast tubulin
Gupta, M. L., Bode, C. J., Georg, G. I., & Himes, R. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1131967100 · Cited by 107
The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.
Gallo, J. M., Li, S., Guo, P., Reed, K., & Ma, J. (2003) · PubMed · Cited by 105
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity
Foà, R., Norton, L., & Seidman, A. D. (1994) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02592403 · Cited by 103
Rice, A., Liu, Y., Michaelis, M. L., Himes, R. H., Georg, G. I., & Audus, K. L. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040114b · Cited by 99
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Gelderblom, H. A. J., Verweij, J., van Zomeren, D. M., Buijs, D., Ouwens, L., Nooter, K., Stoter, G., & Sparreboom, A. (2002) · PubMed · Cited by 99
Salvage chemotherapy with paclitaxel for recurrent primary brain tumors.
Chamberlain, M. C., & Kormanik, P. A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.2066 · Cited by 80
Overcoming Multidrug Resistance in Taxane Chemotherapy
Geney, R., Ungureanu, I. M., Li, D., & Ojima, I. (2002) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2002.161 · Cited by 76
EFFECTS OF DRUG EFFLUX ON CONVECTION-ENHANCED PACLITAXEL DELIVERY TO MALIGNANT GLIOMAS
Tanner, P. G., Holtmannspötter, M., Tonn, J., & Goldbrunner, R. (2007) · Neurosurgery · doi:10.1227/01.neu.0000298922.77921.f2 · Cited by 44
Salvage Chemotherapy with Taxol for Recurrent Anaplastic Astrocytomas
Chamberlain, M. C., & Kormanik, P. A. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006277631745 · Cited by 42
Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme.
Sm, C., Na, B., Pk, S., & Garner (2006) · PubMed · Cited by 31
Cited by
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
CNS Metastases in Breast Cancer: Old Challenge, New Frontiers
Lin, N. U., Amiri-Kordestani, L., Palmieri, D., Liewehr, D. J., & Steeg, P. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0790 · Cited by 1,286
Modern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,006
Helms, H. C., Abbott, N. J., Burek, M., Cecchelli, R., Couraud, P.-O., Deli, M. A., Förster, C., Galla, H. J., Romero, I. A., Shusta, E. V., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16630991 · Cited by 843
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 802
Self-citation
Metadata
- Authors
- Régina, A., Demeule, M., Ché, C., Lavallée, I., Poirier, J., Gabathuler, R., Béliveau, R., & Castaigne, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-09
- Volume
- 155
- Issue
- 2
- Pages
- 185-197
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2108485077
- Cited by
- 368
- References
- 35
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.